Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02186 LUYE PHARMA
RTNominal down2.610 -0.010 (-0.382%)
Others

29/08/2019 11:53

Luye Pharma (02186) interim net up 36% to RMB766.62m

[ET Net News Agency, 29 August 2019] Luye Pharma Group Ltd. (02186) said its profit
attributable to owners of the parent was RMB766.62 million for the six months ended 30
June 2019, a year-on-year increase of 36.2%. The basic earnings per share were RMB23.93
cents. An interim dividend of RMB0.059 (equivalent to HK$0.067) will be distributed.
The revenue was RMB3.13 billion, a year-on-year increase of 42.07%. The gross profit was
RMB2.43 billion, a year-on-year increase of 38.45%. (RC)

Back to Others

Remark: Real time quote last updated: 19/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.